BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35363379)

  • 1. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
    Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
    Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
    Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neither tamoxifen nor aromatase inhibitors increase the risk of Parkinson disease in the UK Biobank cohort.
    Lehrer S; Rheinstein PH
    Cancer; 2022 Aug; 128(15):2997-2998. PubMed ID: 35442525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
    Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
    Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
    Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
    Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
    Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L
    Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
    Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
    Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
    JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
    Seruga B; Zadnik V; Kuhar CG; Marinko T; Cufer T; Zakotnik B; Zorman D; Ocana A; Amir E
    Cancer Invest; 2014 May; 32(4):99-104. PubMed ID: 24548302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Ouédraogo AM; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels DN; Chan KKW; Earle CC
    Breast; 2021 Dec; 60():295-301. PubMed ID: 34728119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
    Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
    Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
    Haque R; Ahmed SA; Fisher A; Avila CC; Shi J; Guo A; Craig Cheetham T; Schottinger JE
    Cancer Med; 2012 Dec; 1(3):318-27. PubMed ID: 23342281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.